The Prescription Drug Sales Representative Disclosure Act
Impact
If enacted, the bill will amend the current statutes within Title 5 of the General Laws relating to businesses and professions. It introduces a systematic framework for tracking pharmaceutical sales representatives and requires the transparency of their activities, which is intended to reduce the influence of sales representatives on prescription practices. This could potentially impact healthcare costs and the prescribing behaviors of medical professionals, as the oversight could discourage undue inducements from representatives.
Summary
House Bill 5679, also known as The Prescription Drug Sales Representative Disclosure Act, aims to regulate the interaction between pharmaceutical sales representatives and healthcare providers. This bill mandates that pharmaceutical manufacturers disclose the identities of their sales representatives to the state's Department of Business Regulation. Additionally, manufacturers are required to provide a comprehensive report of any compensations or gifts given to healthcare providers, ensuring transparency in their interactions.
Contention
The considerations surrounding the bill highlight a contention between advocates for greater transparency in pharmaceutical marketing and concerns about the potential for increased regulation to stifle business operations. Proponents argue that requiring disclosures can help manage rising prescription drug costs by minimizing conflicts of interest. Critics, however, may view it as an additional burden on pharmaceutical companies and believe it might create barriers to efficient sales practices. The civil penalties for non-compliance, which can reach up to $10,000 per violation, further underline the seriousness of the bill's enforcement provisions.
Requires prescription drug manufacturers to file a detailed, updated list of each pharmaceutical sales representative engaged by the manufacturer and to pay an annual fee for each name listed with the department of business regulation.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.